The ICARUS trial is a phase II, open label, multicenter, single arm study conducted to investigate the effcacy, safety, and tolerability of a rechallenge treatment with the first-generation tyrosine kinase inhibitor (TKI) gefitinib in advanced non-small-cell lung cancer (NSCLC) patients carrying activating mutations of the epidermal growth factor receptor (EGFR). The ICARUS trial enrolled 61 patients who were rechallenged with gefitinib at progression after second-line chemotherapy. Serum-derived circulating cell-free DNA (cfDNA) collected before the rechallengefrom a cohort of 29 patients, was retrospectively analyzed for the EGFR exon 19 deletions and for the p.L858R and p.T790M single nucleotide variants (SNV). The analysis of cfDNA detected the same EGFR activating mutation reported in the tumor tissue in 20/29 patients, with a sensitivity of 69%. Moreover, a p.T790M variant was found in 14/29 patients (48.3%). The median progression-free survival (PFS) was 2.7 months for p.T790M positive patients (CI 95% 1.4-3.1 months) versus 3.5 months for the p.T790M negative patients (CI 95% 1.6-5.3 months), resulting in a statistically significant difference (Long rank test p = 0.0180). These findings confirmed the role of the p.T790M mutation in the resistance to first-generation TKIs. More importantly, our data suggest that TKI rechallenge should be guided by biomarker testing.

Esposito Abate, R., Pasquale, R., Sacco, A., Piccirillo, M., Morabito, A., Bidoli, P., et al. (2019). Liquid biopsy testing can improve selection of advanced non-small-cell lung cancer patients to rechallenge with gefitinib. CANCERS, 11(10) [10.3390/cancers11101431].

Liquid biopsy testing can improve selection of advanced non-small-cell lung cancer patients to rechallenge with gefitinib

Bidoli P
;
2019

Abstract

The ICARUS trial is a phase II, open label, multicenter, single arm study conducted to investigate the effcacy, safety, and tolerability of a rechallenge treatment with the first-generation tyrosine kinase inhibitor (TKI) gefitinib in advanced non-small-cell lung cancer (NSCLC) patients carrying activating mutations of the epidermal growth factor receptor (EGFR). The ICARUS trial enrolled 61 patients who were rechallenged with gefitinib at progression after second-line chemotherapy. Serum-derived circulating cell-free DNA (cfDNA) collected before the rechallengefrom a cohort of 29 patients, was retrospectively analyzed for the EGFR exon 19 deletions and for the p.L858R and p.T790M single nucleotide variants (SNV). The analysis of cfDNA detected the same EGFR activating mutation reported in the tumor tissue in 20/29 patients, with a sensitivity of 69%. Moreover, a p.T790M variant was found in 14/29 patients (48.3%). The median progression-free survival (PFS) was 2.7 months for p.T790M positive patients (CI 95% 1.4-3.1 months) versus 3.5 months for the p.T790M negative patients (CI 95% 1.6-5.3 months), resulting in a statistically significant difference (Long rank test p = 0.0180). These findings confirmed the role of the p.T790M mutation in the resistance to first-generation TKIs. More importantly, our data suggest that TKI rechallenge should be guided by biomarker testing.
Articolo in rivista - Articolo scientifico
Liquid biopsy; Non-small-cell lung cancer; P.T790M; Rechallenge; Resistance
English
2019
11
10
1431
open
Esposito Abate, R., Pasquale, R., Sacco, A., Piccirillo, M., Morabito, A., Bidoli, P., et al. (2019). Liquid biopsy testing can improve selection of advanced non-small-cell lung cancer patients to rechallenge with gefitinib. CANCERS, 11(10) [10.3390/cancers11101431].
File in questo prodotto:
File Dimensione Formato  
10281-260550.pdf

accesso aperto

Tipologia di allegato: Publisher’s Version (Version of Record, VoR)
Dimensione 824.66 kB
Formato Adobe PDF
824.66 kB Adobe PDF Visualizza/Apri

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/10281/260550
Citazioni
  • Scopus 10
  • ???jsp.display-item.citation.isi??? 7
Social impact